A Framework Agreement on Trade and Investment (TIFA) is a trade pact that establishes a framework for expanding trade and resolving open disputes between countries. The drug DTCA database is still growing, but IL has shown that DTCA stimulates demand for patented drugs (which increases expenses) and affects rational prescribing [45]. Spending on drug promotion in the United States focuses on new drugs, which are likely to provide a significant return on investment, and television advertising focuses more on promotion than on education [46]. A recent systematic verification of the impact on prescription, when physicians receive information directly from pharmaceutical companies, found evidence of a link with a deterioration in prescription adequacy and an increase in prescription costs and frequency [47]. Specific provisions relating to the intellectual property of TRIPS-Plus in recent regional drug trade agreements. The file identifies the item numbers/sections contained in recent regional trade agreements, in which there are specific provisions relating to the intellectual property of TRIPS Plus, which are relevant to drugs. The abolition of ISDS, not its modification, would require dependence on national judicial systems in the country where the investment is made, or a form of state settlement [73] or new mechanisms, such as those provided for CETA. Other alternatives include a Global Investment Court or, as proposed by the OECD, a Multilateral Investment Tribunal [74,75,76]. Agreements reached by South Africa, Brazil and other countries indicate national judicial solutions [77]. It is therefore necessary to better understand the intersection points and potential impact of trade agreements on national drug policy in order to inform health and human rights assessments Under Note 2 of trade agreements being negotiated (to the extent that negotiating texts have been published or disclosed) or implemented in the future, and to study their implications after their implementation. This document aims to address this gap by identifying the provisions of recently negotiated regional trade and investment agreements relevant to pharmaceutical policy and practice, following the paths that will allow them to influence the objectives of pharmaceutical policy (how to interact with pharmaceutical policy in order to have an impact on certain pharmaceutical policy objectives) and to develop a framework for analyzing the impact of trade and investment agreements on pharmaceutical policy and access to medicines.